Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update

作者：Kevin McFarthing, Gary Rafaloff, Marco A. S. Baptista, Leah Mursaleen, Rosie Fuest, Richard K H Wyse, Simon Stott · 发表于：Journal of Parkinson s Disease · 年份：2022 · DOI：10.3233/jpd-229002 · 被引用次数：119 · 研究领域：Parkinson's Disease Mechanisms and Treatments、Pharmacological Receptor Mechanisms and Effects、Neurogenetic and Muscular Disorders Research

BACKGROUND: As the international community dealt with the ongoing COVID-19 pandemic, important progress continued to be made in the development of new drug-based therapies for the neurodegenerative condition of Parkinson's disease (PD) in 2021. This progress included both "symptomatic treatments" (ST - improves/reduces symptoms of the condition) and "disease modifying treatments" (DMT - attempts to delay/slow progression by addressing the underlying biology of PD), which can be categorised further based on their mechanisms of action and class of drug. OBJECTIVE: This report continues previous efforts to provide an overview of the pharmacological therapies - both ST and DMT - in clinical trials for PD during 2021- 2022, with the aim of creating greater awareness and involvement in the clinical trial process. We also hope to stimulate collaboration amongst all stakeholders, including industry, academia, advocacy organizations, and most importantly patient community. METHODS: We conducted a review of clinical trials of drug therapies for PD using trial data obtained from the ClinicalTrials.gov and World Health Organisation (WHO) registries, and performed a breakdown analysis of studies that were active as of January 31st 2022. We also assessed active drug development projects that had completed one clinical phase but were yet to start the next. RESULTS: There was a total of 147 clinical trials registered on the ClinicalTrials.gov website as active during the period of analysis. ...